A detailed history of Susquehanna International Group, LLP transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 991,649 shares of IOVA stock, worth $9.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
991,649
Previous 1,817,000 45.42%
Holding current value
$9.27 Million
Previous $26.9 Million 70.46%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$7.78 - $14.19 $6.42 Million - $11.7 Million
-825,351 Reduced 45.42%
991,649 $7.95 Million
Q1 2024

May 07, 2024

BUY
$7.59 - $17.47 $1.66 Million - $3.81 Million
218,070 Added 13.64%
1,817,000 $26.9 Million
Q4 2023

Feb 14, 2024

BUY
$3.3 - $8.89 $1.17 Million - $3.15 Million
353,893 Added 28.42%
1,598,930 $13 Million
Q3 2023

Nov 14, 2023

BUY
$4.44 - $8.79 $3.91 Million - $7.74 Million
881,054 Added 242.06%
1,245,037 $5.66 Million
Q2 2023

Aug 11, 2023

SELL
$5.36 - $9.06 $1.31 Million - $2.22 Million
-245,192 Reduced 40.25%
363,983 $2.56 Million
Q1 2023

May 16, 2023

BUY
$5.53 - $8.22 $2.31 Million - $3.43 Million
417,427 Added 217.7%
609,175 $3.72 Million
Q4 2022

Feb 14, 2023

SELL
$5.62 - $10.0 $673,697 - $1.2 Million
-119,875 Reduced 38.47%
191,748 $1.23 Million
Q3 2022

Nov 14, 2022

BUY
$9.53 - $13.11 $1.89 Million - $2.6 Million
198,343 Added 175.09%
311,623 $2.99 Million
Q2 2022

Aug 15, 2022

SELL
$6.38 - $18.33 $1.95 Million - $5.59 Million
-304,873 Reduced 72.91%
113,280 $1.25 Million
Q1 2022

May 16, 2022

SELL
$12.38 - $19.1 $3.43 Million - $5.29 Million
-276,847 Reduced 39.83%
418,153 $6.96 Million
Q4 2021

Feb 14, 2022

BUY
$16.55 - $27.63 $1.22 Million - $2.04 Million
73,961 Added 11.91%
695,000 $13.3 Million
Q3 2021

Nov 15, 2021

SELL
$20.35 - $26.63 $3.96 Million - $5.19 Million
-194,809 Reduced 23.88%
621,039 $15.3 Million
Q2 2021

Aug 11, 2021

BUY
$16.33 - $33.07 $11.2 Million - $22.6 Million
684,759 Added 522.36%
815,848 $21.2 Million
Q1 2021

May 17, 2021

BUY
$28.67 - $52.59 $1.67 Million - $3.06 Million
58,180 Added 79.8%
131,089 $4.15 Million
Q4 2020

Feb 16, 2021

SELL
$28.04 - $50.26 $19.1 Million - $34.3 Million
-682,028 Reduced 90.34%
72,909 $3.38 Million
Q3 2020

Nov 16, 2020

BUY
$27.75 - $36.3 $7.06 Million - $9.24 Million
254,452 Added 50.84%
754,937 $24.9 Million
Q2 2020

Aug 14, 2020

SELL
$27.21 - $41.0 $4.4 Million - $6.64 Million
-161,876 Reduced 24.44%
500,485 $13.7 Million
Q1 2020

May 15, 2020

BUY
$19.54 - $38.85 $10.5 Million - $20.8 Million
536,277 Added 425.33%
662,361 $19.8 Million
Q3 2019

Nov 14, 2019

BUY
$17.99 - $26.0 $896,819 - $1.3 Million
49,851 Added 65.39%
126,084 $2.29 Million
Q2 2019

Aug 16, 2019

BUY
$9.78 - $24.52 $535,924 - $1.34 Million
54,798 Added 255.65%
76,233 $1.87 Million
Q2 2019

Aug 14, 2019

SELL
$9.78 - $24.52 $281,194 - $704,999
-28,752 Reduced 57.29%
21,435 $526,000
Q4 2017

Feb 14, 2018

SELL
$6.65 - $9.25 $4.34 Million - $6.04 Million
-652,886 Reduced 92.86%
50,187 $401,000
Q3 2017

Nov 14, 2017

BUY
$4.45 - $8.55 $3.13 Million - $6.01 Million
703,073
703,073 $5.45 Million

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.48B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.